Cybin wins new Buy from Guggenheim: potential to challenge J&J's Spravato cited [Seeking Alpha]
Cybin Inc. (NYSE: CYBN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.
Podcast: How Trump's tariffs will impact clinical trials [Yahoo! Finance]
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at HC Wainwright from $190.00 to $150.00. They now have a "buy" rating on the stock.
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $86.00 to $73.00. They now have a "buy" rating on the stock.